Top

Current Bladder Dysfunction Reports

Published in:

01-12-2019 | Stress Incontinence | Stress Incontinence and Prolapse (WS Reynolds, Section Editor)

Hormone Replacement for Pelvic Floor Disorders

Authors: Joseph Panza, W. Stuart Reynolds

Published in: Current Bladder Dysfunction Reports | Issue 4/2019

Abstract

Purpose of Review

The purpose of this review article is to summarize the recent literature regarding the effect of hormone replacement therapy on pelvic floor disorders and its role as a preventative or treatment option.

Recent Findings

The recent evidence describing the effect of hormone replacement therapy on pelvic floor disorders is mainly limited to cohort studies, systematic reviews, and secondary analysis of randomized controlled trials such as the Women’s Health Initiative and Nurses’ Health Study. There are few quality randomized controlled trials, especially within the last 5 years on this topic. The data that does exist does not show hormone therapy to be beneficial in the treatment or prevention of pelvic floor disorders. In fact, it may worsen urinary and fecal incontinence when given systemically. The exception to this is the local application of vagina estrogen, where it may be of some benefit in the treatment of urinary incontinence. Local application has been shown to be beneficial when treating genitourinary syndrome of menopause and in the prevention of recurrent urinary tract infections.

Summary

There is a paucity of quality data regarding the secondary effects and use of hormone replacement as a treatment for pelvic floor disorders. Given the lack of studies, limited efficacy, and possible side effects, it should not be offered as first-line or single treatment for pelvic floor disorders such as urinary or fecal incontinence and pelvic organ prolapse. It may be used as a treatment for genitourinary syndrome of menopause and for prevention of urinary tract infections when placed locally in the vagina.

Hallock JL, Handa VL. The epidemiology of pelvic floor disorders and childbirth. Obstet Gynecol Clin N Am. Elsevier Inc. 2016;43(1):1–13. https://doi.org/10.1016/j.ogc.2015.10.008.CrossRef

Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. women. Obstet Gynecol. 2009;114(6):1278–83. https://doi.org/10.1097/AOG.0b013e3181c2ce96.CrossRefPubMed

Lince SL, van Kempen LC, Vierhout ME, Kluivers KB. A systematic review of clinical studies on hereditary factors in pelvic organ prolapse. Int Urogynecol J. 2012;23(10):1327–36. https://doi.org/10.1007/s00192-012-1704-4.CrossRefPubMedPubMedCentral

• ACOG Practice Bulletin No 141. Management of menopausal symptoms. 2018; 1–15. This reference is of importance as it provides evidence-based guidelines on the treatment of menopausal symptoms (including vagina symptoms) as supported by the American College of Obstetrics and Gynecology. It has a large amount of information on hormone therapies, their routes of administration, and side effects.

Smith P. Estrogens and the urogenital tract. Acta Obstet Gynecol Scand Suppl. 1993;157:1–26.PubMed

Brubaker L, Carberry C, Nardos R, Carter-Brooks C, Lowder JL. American urogynecologic society best-practice statement: recurrent urinary tract infection in women. Female Pelvic Med Reconstr Surg. 2018;24(5):321–35. https://doi.org/10.1097/SPV.0000000000000550.CrossRefPubMed

Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Incontinence Group, editor. Cochrane Database Syst Rev. 2012;30(1):37–86.

McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14:103–15.CrossRef

Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005;52(Suppl 1):S46–52.CrossRef

10.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353–68. https://doi.org/10.1001/jama.2013.278040.CrossRefPubMed

11.

Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and post- menopausal women. Cochrane Database Syst Rev. 2012;(7):CD004143. https://doi.org/10.1002/14651858.CD004143.pub4.

12.

Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103–11.CrossRef

13.

Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association/International Continence Society joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5. https://doi.org/10.1007/s00192-009-0976-9.CrossRefPubMed

14.

Nitti VW. Prevalence of urinary incontinence. Rev Urol. 2001;3(Suppl 1):S2–6.PubMedPubMedCentral

15.

Capobianco G, Madonia M, Morelli S, Dessole F, De Vita D, Cherchi PL, et al. Management of female stress urinary incontinence: a care pathway and update. Maturitas. 2018;109:32–8. https://doi.org/10.1016/j.maturitas.2017.12.008.CrossRefPubMed

16.

American College of Obstetricians and Gynecologists. Urinary incontinence in women. Practice Bulletin No. 155. Obstetetics and Gynecology. 2018;126:e66–81.

17.

•• Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935–48 This reference is of importance given its large, varied patient population and though it is a secondary analysis, the original study was a multicenter double-blind, placebo-controlled, randomized clinical trial. CrossRef

18.

Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol. 2004;103:254–60.CrossRef

19.

Steinauer JE, Waetjen LE, Vittinghoff E, et al. Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol. 2005;106:940–5.CrossRef

20.

Jackson S, James M, Abrams R. The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG. 2002;109(3):339–44.CrossRef

21.

Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2011;285(2):397–403.CrossRef

22.

Bump RC, Mattiasson A, Bø K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996;175:10–7.CrossRef

23.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.CrossRef

24.

Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clinic Proc. Mayo Foundation for Medical Education and Research. 2017;92(12):1842–9. https://doi.org/10.1016/j.mayocp.2017.08.019.CrossRef

25.

Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Incontinence Group, editor. Cochrane Database Syst Rev. 2010;15(2):241–35.

26.

Wasenda EJ, Kamisan Atan I, Subramaniam N, Dietz HP. Pelvic organ prolapse: does hormone therapy matter? Menopause. 2017;24(10):1185–9. https://doi.org/10.1097/GME.0000000000000898.CrossRefPubMed

27.

Cardenas-Trowers OO, Borgstrom M, Addis I. Associations between type and route of hormone use on urinary incontinence and pelvic organ prolapse in premenopausal and postmenopausal women. Female Pelvic Med Reconstr Surg. 2018;24(2):100–4. https://doi.org/10.1097/SPV.0000000000000493.CrossRefPubMed

28.

Rahkola-Soisalo P, Savolainen-Peltonen H, Gissler M, Hoti F, Vattulainen P, Ylikorkala O, et al. Postmenopausal hormone therapy is accompanied by elevated risk for uterine prolapse. Menopause. 2019;26(2):140–4. https://doi.org/10.1097/GME.0000000000001173.CrossRefPubMed

29.

Tyagi T, Alarab M, Leong Y, Lye S, Shynlova O. Local oestrogen therapy modulates extracellular matrix and immune response in the vaginal tissue of post-menopausal women with severe pelvic organ prolapse. J Cell Mol Med. 2019;23(4):2907–19. https://doi.org/10.1111/jcmm.14199.CrossRefPubMedPubMedCentral

30.

Bharucha AE, Dunivan G, Goode PS, Lukacz ES, Markland AD, Matthews CA, et al. Epidemiology, pathophysiology, and classification of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. Am J Gastroenterol. Nature Publishing Group. 2014;110(1):127–36.CrossRef

31.

Bharucha AE, Zinsmeister AR, Locke GR, et al. Risk factors for fecal incontinence: a population-based study in women. Am J Gastroenterol. 2006;101:1305–12.CrossRef

32.

Goode PS, Burgio KL, Halli AD, et al. Prevalence and correlates of fecal incontinence in community-dwelling older adults. J Am Geriatr Soc. 2005;53:629–35.CrossRef

33.

• Staller K, Townsend MK, Khalili H, Mehta R, Grodstein F, Whitehead WE, et al. Menopausal hormone therapy is associated with increased risk of fecal incontinence in women after menopause. Gastroenterology. 2017;152(8):1915–1921.e1. https://doi.org/10.1053/j.gastro.2017.02.005Given the mixed results from prior studies on fecal incontinence and its association with hormone therapy use, this reference is important because of its large patient population and clear link between HRT and fecal incontinence use. CrossRefPubMedPubMedCentral

34.

Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753–6.CrossRef

35.

Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180(5):1072–9.CrossRef

36.

Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147–56. https://doi.org/10.1097/AOG.0000000000000526.CrossRefPubMedPubMedCentral

37.

Anger J, et al. American Urologic Association. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. 2019:1–36.

38.

Raz R. Urinary tract infection in postmenopausal women. Korean J Urol. 2011;52(12):801–8.CrossRef

39.

Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause. 2013;20(9):888–902. https://doi.org/10.1097/GME.0b013e3182a122c2.

40.

Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013;10(6):1575–84. https://doi.org/10.1111/jsm.12125.CrossRefPubMed

41.

Constantine GD, Simon JA, Pickar JH, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017;24(4):409–16. https://doi.org/10.1097/GME.0000000000000786.CrossRefPubMedPubMedCentral

42.

Capobianco G, Wenger JM, Meloni GB, Dessole M, Cherchi PL, Dessole S. Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. Arch Gynecol Obstet. 2014;289(3):601–8. https://doi.org/10.1007/s00404-013-3030-6.CrossRefPubMed

43.

American College of Obstetricians and Gynecologists. Management of gynecologic issues in women with breast cancer. Practice Bulletin No. 126. Obstetetics and Gyencology. 2012; 119:666–82.

44.

Bachmann GA, Leiblum SR. The impact of hormones on menopausal sexuality: a literature review. Menopause. 2004;11(1):120–30.CrossRef

45.

Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259–63.CrossRef

46.

Cardenas-Trowers O, Meyer I, Markland AD, Richter HE, Addis I. A review of phytoestrogens and their association with pelvic floor conditions. Female Pelvic Med Reconstr Surg. 2018;24(3):193–202. https://doi.org/10.1097/SPV.0000000000000559.CrossRefPubMedPubMedCentral

47.

Thompson LU, Boucher BA, Liu Z, et al. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer. 2006;54(2):184–201.CrossRef

48.

Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139(10):4252–63.CrossRef

49.

Tomaszewski J, Adamiak A, Skorupski P, et al. Effect of 17 beta-estradiol and phytoestrogen daidzein on the proliferation of pubocervical fascia and skin fibroblasts derived from women suffering from stress urinary incontinence. Ginekol Pol. 2003;74(10):1410–4.PubMed

50.

Owen SJ, Rose’Meyer RB, Massa HM. Dietary phytoestrogens maintain contractile responses to carbachol with age in the female rat isolated bladder. Life Sci. 2011;89(7–8):213–20.CrossRef

51.

Marañon JA, Lozano C, Martinez-Campesino L, et al. Clinical study: effect of supplementation with high genistein soybean isoflavones and pumpkin standardized extract on urinary incontinence in western perimenopausal women. J Gynecol Womens Health. 2017;4(1):555627. https://doi.org/10.19080/JGWH.2017.04.555627.CrossRef

Title: Hormone Replacement for Pelvic Floor Disorders
Authors: Joseph Panza
W. Stuart Reynolds
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Stress Incontinence
Fecal Incontinence
Urinary Incontinence
Urinary Tract Infection
Urinary Incontinence
Genitourinary Syndrome of Menopause
Estrogens
Estriol
Published in: Current Bladder Dysfunction Reports / Issue 4/2019
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-019-00536-5

At a glance: The STEP trials

Springer Medicine

Hormone Replacement for Pelvic Floor Disorders

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2019

Advances in Pharmacotherapy for the Treatment of Overactive Bladder

Consequences of Pelvic Radiotherapy on Urinary Function in Women

Pharmacotherapy for Interstitial Cystitis/Bladder Pain Syndrome

Is Vaginal Laser Effective for Overactive Bladder? Results of a Systematic Review

Overactive Bladder in Diabetes Mellitus

Rectourethral Fistula—Review of Current Practices, Developments, and Outcomes